Zelgen Biopharmaceutical (688266.SH): New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Accepted

date
20:21 13/10/2026
avatar
GMT Eight
Zelgen Biopharmaceutical (688266.SH) announced that recently, the company received the "Notice of Acceptance" issued upon approval by the National Medical Products Administration (NMPA). The New Drug Application (NDA) submitted by the company for Gecacitinib Hydrochloride Tablets for the treatment of active ankylosing spondylitis has been accepted. This is the third indication for which Gecacitinib Hydrochloride Tablets has applied for new drug marketing approval. Gecacitinib Hydrochloride (formerly known as Jacktinib Hydrochloride) is a novel JAK inhibitor drug independently developed by the company, and the company owns the independent intellectual property rights to this product.
Zelgen Biopharmaceutical (688266.SH) announced that recently, the company received a Notice of Acceptance issued upon approval by the National Medical Products Administration (NMPA). The New Drug Application (NDA) submitted by the company for Gecacitinib Hydrochloride Tablets for the treatment of active ankylosing spondylitis has been accepted. This is the third indication for which Gecacitinib Hydrochloride Tablets has applied for new drug marketing approval. Gecacitinib Hydrochloride (formerly known as Jackitinib Hydrochloride) is a novel JAK inhibitor independently developed by the company, and the company owns the independent intellectual property rights to this product.